












hPL: Physiologic and Pathophysiologic 
Observations 
FRANK /. ZLA TNIK, MD, MICHAEL W. VARNER, MD, 
KA THERINE S. HA lISER, MD, AND SYL VIA S. LEE, MS 
Serum human placental lactogen (hPL) levels were studied 
in 806 women in late pregnancy. The hPL levels were posi-
tively correlated with birth weight but were unrelated to 
maternal age, parity, socioeconomic status, or the sex of the 
newborn. The hPL levels peaked at 31 weeks' gestation and 
then declined moderately. An individual's hPL levels in 
late pregnancy are quite constant week to week. Patients 
with severe chronic hypertension have low hPL values; 
those carrying twins have high values. 
Despite an extensive literature on serum human pla-
cental lactogen (hPL) [also called human chorionic so-
matomammotropin (hCS)], several basic clinical ques-
tions concerning this placental protein hormone 
remain unresolved. 1 We have recently completed a 
relatively large study of serial hPL determinations in 
late pregnancy. The usefulness of hPL as a predictor of 
perinatal outcome is the subject of a separate report. 2 
This paper presents data relevant to the following 
questions: 1) What is the relationship between hPL 
levels in late pregnancy and the birth weight of the 
newborn? 2) What is the pattern of hPL values by 
week in late pregnancy? 3) How consistent are an indi-
vidual's weekly hPL values in late pregnancy? and 4) 
What are the hPL values in certain abnormal condi-
tions of pregnancy? 
Materials and Methods 
Volunteers from our high-risk clinic and routine ante-
partum clinics were enrolled in the study from Sep-
tember 1976 through June 1977. The only entry re-
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quirements were the presence of a living fetus and the 
absence of labor. At each antepartum visit from 34 
weeks' gestation until delivery, a serum sample was 
obtained which was analyzed in duplicate for hPL by 
radioimmunoassay using a stafldard commercial kit 
(New England Nuclear). Hospitalized patients had 
weekly samples taken. The separated serum samples 
were frozen until analysis. The intraassay coefficient 
of variation was 3.9%; the interassay coefficient of var-
iation was 13.9%. 
The hPL results were not reported. Therefore, ob-
stetric management was not influenced by the serum 
hPL levels. 
Following delivery, data sheets were completed us-
ing information provided by the hospital records of 
the mothers and newborns. Demographic data, identi-
fied risk factors, maternal course during pregnancy, 
fetal surveillance test results, neonatal outcome data, 
and hPL values were recorded and subsequently trans-
ferred to magnetic tape for computer analysis. 
Eight hundred six patients with at least 1 hPL deter-
mination delivered at University Hospitals. They and 
their 818 offspring (12 sets of twins) form the study 
population. . 
Two hundred forty-two babies were delivered to 
women whose pregnancies were defined as being at 
risk prior to labor, because 1 or more of the following 
had occurred: antepartum admission to the hospital, 
antepartum fetal heart rate (FHR) testing, urinary es-
trogen determination, amniocentesis for fetal maturity 
testing, and/or a t:. optical density (00) qetermination 
at 450 nm. Factors accounting for the at-risk status are 
listed in Table 1. Risk patients were placed in group 1 
if they spontaneously went into labor and were placed 
in group 2 if delivery was effected because of concern 
for the mother and/or fetus. 
Five hundred seventy-six babies were delivered to 
women not considered to be at risk prior to labor. 
They were not admitted to the hospital prior to labor, 
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Table 1. Antepartum Factors Accounting for At-Risk 
Status 
Factor Group 1 Group 2 Total 
Postmaturity (known 
and suspected) 39 20 59 
Premature rupture 
of the membranes 22 31 53 
Chronic hypertension 12 19 31 
Preeclampsia 6 18 24 
Third-trimester 
bleeding 15 5 20 
Diabetes mellitus 1 11 12 
Suspected IUGR 10 2 12 
Twins 10 0 10 
Isoimmunization 4 4 8 
Previous cesarean section 10 1 11 
Renal disease 3 3 6 
Premature labor 4 1 5 
Bad obstetric history 2 3 5 
Autoimmune disease 3 0 3 
Cardiac disease 2 1 3 
Other 24 5 29 
167 124 291" 
• 242 births---certain patients had multiple risk factors; 576 births 
occurred in patients who were not at risk antepartum. 
IUGR = Intrauterine growth retardation. 
nor did they have antepartum FHR testing, urinary es-
trogen assays, or third-trimester amniocenteses per-
formed. Some of these patients may have been high 
risk because of maternal age, socioeconomic status, or 
other factors, but the specific clinical and laboratory 
measures generally un4ertaken on our service in preg-
nancies we consider to be at risk were absent. 
If there was a discrepancy between the clinical esti-
mate of gestational age and that suggested by physical 
examination of the newporn, the latter was chosen as 
indicating gestational age. Appropriateness of birth 
weight for gestational age was determined from the 
Colorado growth chart.' Severe hypertension was de-
fined as a usual rather ti1an a peak blood pressure of 
2:140/90 mmHg. 
In diabetic pregnancies the average total daily in-
sulin requirement in the third trimester was compared 
with the nonpregnant insulin dosage for each patient. 
Two patients with an insulin increase of > 100% were 
compared with 7 patients with an increase of < 100%. 
The 806 women studied had a total of 1986 serum 
samples analyzed for hPL. The number of samples per 
patient ranged from 1 to 8 (Table 2). Seventy-one per-
cent of the patients had their fjnal sample obtained 
within 7 days of delivery and 81% within 10 days of 
delivery. 
Statistical methods used were as follows: hPL-birth 
weight relationships: correlation coefficients and mul-
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tiple regression analyses4 ; birth weight-gestational 
age-hPL relationships: Bonferroni t testS; hPL weekly 
pattern: Duncan's multiple range test6 ; individual pa-
tient hPL consistency: intraclass correlation coeffi-
cients'; comparison of mean hPL levels in various con-
ditions: Student's t test! 
Results and Discussion 
Relationship Between hPL and Birth Weight 
Although hPL levels are generally considered to be 
Significantly correlated in a positive manner with pla-
cental weight, the literature is divided on the question 
of the relationship between hPL levels in late preg-
nancy and birth weight. 1 Certain reports have de-
scribed a positive relatjonship7,"; others have not.9 - 11 
The mean hPL level for each of the 794 women who 
was delivered' of a single fetus was determined, and 
these were correlated with the birth weights of the 
newborns, Mean hPL levels in late pregnancy were 
significantly correlated with birth weight, r = 0.173 (p 
< 0.001). Other factors positively correlated with birth 
weight were: gestational age, r = 0.360 (p < 0.001), 
male sex of the newborn, r = 0.159 (P < O.OOn and 
multiparity, r = 0,070 (p < 0.05). Birth weight was un-
related to the patient's socioeconomic status. Of the 
factors studied, gestational age was demonstrated by 
multiple regression analyses to be the most highly 
correlated with birth weight. The mean hPL correla-
tion was stronger than that of the parity of the mother 
or of the sex of the newborn. Mean hPf,. levels were 
unrelated to maternal age, socioeconomic status, par-
ity, or sex of the newborn. Figure 1 demonstrates sig-
nificant mean hPL differences (p < 0.01) among pa-
tients who were delivered of small-, appropriate-, or 
large-for-gestational-age babies. 
Since serum hPL levels are related to placental 
weight, and since newborn and placental weights are 
positively correlated, it is not surprising that our data 
Table 2. The Number of Serum Samples per Patient 
Analyzed for hPL 
No. of samples No, of patients (%) 
1 318 (39) 
2 179 (22) 
3 112 (14) 
4 84 (10) 
5 61 (8) 
6 36 (4) 
7 11 (1) 
8 5 (1) 
806 (100) 
hPL '" Human placental lactogen. 
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Figure 1. Mean hPL levels as related to birth weight-gestational 
age categories. SGA = Small for gestational age; AGA = appropriate 
for gestational age; LGA = large for gestational age. Lines above 
bars represent 1 standard deviation. 
demonstrate a relationship between mean hPL levels 
in late pregnancy and birth weight. As can be seen in 
Figure 1, however, considerable overlap in hPL levels 
exists among the different birth weight-gestational age 
categories. This helps explain the limited value of low 
hPL levels in identifying small-for-gestational-age fe-
tuses in a general obstetric population! 
Weekly hPL Pattern in Late Pregnancy 
Several patterns of serum hPL levels in late pregnancy 
have been described .•. 10.12-1. Peak values have been re-
ported at 35," 37-38,15 39,13 and 40 weeks' gestation.'6 
Certain authors describe a decline in late preg-
nancy,13.1S.16 while others describe a plateau after 34'2 or 
36 weeks' gestation. 18 
Our data, based on 1983 determinations, are pre-
sented in Figure 2 (3 determinations for week 43 have 
been excluded). Peak mean hPL levels (8.8 pg/ml) oc-
10 
~ 9 (122;(128; (231; (276; (354) (421} (309; (107) (35) 
Weeks' Gestation 
Figure 2. Mean hPL levels by weeks' gestation. The number of 
samples tested for each week are in parentheses. 
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curred at 37 weeks' gestation. This level is signifi-
cantly higher than that at 34 weeks' gestation (7.8 p.g/ 
ml; P < 0.05). After 37 weeks' gestation there was a 
moderate decline in mean hPL levels to 7.1 p.g/ml at 42 
weeks' gestation. The 42-week value is significantly 
lower than all of the others (P < 0.05). As has pre-
viously been reported,'9 the distribution of hPL values 
in late pregnancy is skewed with a greater spread of 
values above than below the mean. 
Individual Consistency of hPL Values 
Although an individual's hPL levels in late pregnancy 
may vary within a day by ± 15%,19 there is little infor-
mation regarding the consistency of an individual pa-
tient's hPL values week to week in late pregnancy. To 
estimate this consistency in our study population, in-
traclass correlation or reliability coefficients were com-
puted separately for those patients tested 2, 3, 4, or 
more times in late pregnancy. Due to computational 
limitations, the coefficients summarized in Table 3 
were computed separately for the number of samples 
tested in late pregnancy. 
The reliability coefficient quantifies the consistency 
of hPL determinations from week to week within a 
subject. If the hPL readings show little variation rela-
tive to the variation among patients, the reliability co-
efficient will be significantly larger than 0, although by 
definition it will never be greater than 1. The levels of 
significance (Table 3) indicate that the reliability of 
hPL readings is greater than 0, regardless of the num-
ber of times a patient is tested in late pregnancy. This 
suggests that multiple weekly samples from an indi-
vidual in late pregnancy may provide little more infor-
mation than that provided by 1 or 2 samples. 
hPL Levels in Various Conditions 
Serum hPL levels reflect placental mass. Therefore one 
might predict that certain conditions would be associ-
ated with high or low hPL levels. The 12 women with 
twins in our study population had a mean hPL level of 
12.7 pg/ml, which was significantly higher (P < 0.01) 
Table 3. Reliability Coefficients Related to the Number of 
Samples per Patient 
No. of No. of Reliability 
samples patients coefficient Significance 
2 179 0.71 P<0.OO1 
3 112 0.64 P<O.(XH 
4 84 0.66 P<O.OOI 
5 61 0.74 P<O.OOI 
6 36 0.64 P<O.OOI 
7 11 0.51 P<O.OOI 
8 5 0.33 P<O.Ol 
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than the mean level of patients with singleton preg-
nancies (8.3 ",giml). Patients with severe hypertension 
in our study population (N = 9) had a mean hPL level 
of 5.9 ",gimi, which was significantly lower (P < 0.01) 
than that of the remainder of the study population (8.3 
",glml). No other statistically significant differences in 
mean hPLs for the conditions listed in Table 1 were 
found. This may reflect in part small numbers in some 
of the categories and also the heterogeneity of the pa-
tients in each category, with some having mild or no 
disease (eg, Rh-sensitized patients carrying Rh-nega-
tive fetuses, and patients with suspected intrauterine 
growth retardation delivering appropriate-for-gesta-
tional-age babies). 
Because hPL affects carbohydrate and lipid metabo-
lism and is thought to be in part responsible for the 
diabetogenic effects of pregnancy, the relationship of 
hPL levels to the insulin requirements of pregnant dia-
betics has received previous attention. Although Soler 
et a120 could not relate the increased insulin require-
ment during pregnancy to hPL levels, Ursell and co-
workers" found significantly higher hPL levels in pa-
tients whose insulin requirements rose> 100% during 
pregnancy. 
The few patients in this study who required insulin 
prior to pregnancy (N = 9) did not demonstrate a rela-
tionship between the incremental insulin required and 
hPL levels. 
Conclusions 
The hPL levels in late pregnancy are positively corre-
lated with birth weight. The hPL levels peak at about 
37 weeks' gestation and then decline. This decline 
continues until at least 42 weeks' gestation. In late 
pregnancy, individuals generally show little variation 
in hPL levels from week to week. The hPL levels re-
flect placental mass. They are high in twin pregnancy 
and low in patients with severe chronic hypertension. 
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